Sensei Biotherapeutics Inc (SNSE) Stock Price, Quote & News

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

Mjoc Jan. 14 at 8:22 PM

$SNSE can we get this thing ripping already? @JACK_TRADZ

0 · Reply

TheSniperGuy Jan. 14 at 4:03 PM

$SNSE If you're seriouse about catching small-cap runners or any runners early you learn by yourself!

0 · Reply

Mach777 Jan. 13 at 4:03 PM

$SNSE It’s been a great month. What would this do with some volume…

0 · Reply

Guptasulo Jan. 12 at 1:37 PM

$AGEN $INKT $IMMX $SNSE France just did something extraordinary. They granted national, reimbursed AAC access for Agenus’ BOT + BAL across three different cancers: • MSS colorectal • Platinum-resistant ovarian • Soft-tissue sarcoma That kind of multi-tumor blanket access is extremely rare — it means regulators see a tumor-agnostic immune mechanism, not a one-off drug. This connects directly with MiNK (INKT): Both platforms target immune reprogramming in refractory, “cold” tumors — not chemo, not radiation, but true immune modulation. Together, Agenus + MiNK are building a platform immune engine for cancers that have already failed standard therapies. No chemo. No radiation. Just immune system reboot. This is how next-gen oncology platforms are born.

2 · Reply

ChartChartist Jan. 10 at 11:44 PM

$SCNI sitting $MTEX lets go sexy $SNSE climbing channel $ENVB idk okay tho $HWH lets gooo. #1 ticker hwh , get on it

0 · Reply

SuperGreenToday Jan. 9 at 11:02 PM

$SNSE

0 · Reply

Biotechguy21 Jan. 9 at 12:47 PM

$AGEN $IMMX $INKT $SNSE two of these are huge pos stocks. And add $PTIX and you have a trifecta of 💩

0 · Reply

Guptasulo Jan. 9 at 7:00 AM

$INKT $AGEN $IMMX $SNSE INKT here; The University of Wisconsin–Madison + MiNK press release John Tracks shared; https://finance.yahoo.com/new s/mink-therapeutics-university-wisconsin-madison-170000383.html This GvHD trial is funded by NIH (NIAID) STTR + UW philanthropic grants. NIH STTR funding is not early discovery — it is platform validation and expansion. The key is iNKT cells — MiNK’s off-the-shelf immune regulators that are already being tested in: • Refractory gastric cancer • Solid tumors • ARDS (severe pulmonary inflammation) • Now GvHD / transplant immune regulation These are all expressions of the same immune engine. 2026 we get: A) RGC 48-week OS update (any time) B) Full 52-week RGC dataset later in the year C) ARDS immune-modulation data D) NIH- and UW-funded GvHD Day-100 readout Combined with $AGEN’s BOT/BAL backbone, this is a multi-indication immune platform being validated by the U.S. government — not a one-drug biotech. This is not a normal microcap biotech.

1 · Reply

Katherine_Clayton_11 Jan. 8 at 3:55 PM

$SNSE NERC doesn’t need to predict a collapse for this to matter. They just need to show that large load growth is a stress factor. Stress factors create policy responses, and policy responses create CAPEX waves. CAPEX waves create multi-year beneficiaries. This is why the power/resilience stack keeps getting stronger as AI load keeps piling on - it’s a compounding setup, not a single event 🚀

0 · Reply

IAmMsMoneyMaker Jan. 7 at 9:29 PM

$AFJK Is set to RUN! 🚀 🚀 🚀 🚀 So are…$PAVM & $SNSE ALL ABOUT THE TIMING!!! ⏳ ⌛️

0 · Reply

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

Nov 14, 2025, 7:30 AM EST - 2 months ago

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 9:00 AM EDT - 2 months ago

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Oct 17, 2025, 8:00 AM EDT - 3 months ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sep 23, 2025, 7:30 AM EDT - 4 months ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 3, 2025, 8:00 AM EDT - 4 months ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 7:30 AM EDT - 5 months ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 7:30 AM EDT - 6 months ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jun 13, 2025, 7:30 AM EDT - 7 months ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 9 months ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 10 months ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 10 months ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 10 months ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 1 year ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 1 year ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 1 year ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Jun 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 18, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 30, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

Mar 28, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Mar 21, 2023, 7:30 AM EDT - 3 years ago

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Mjoc Jan. 14 at 8:22 PM

$SNSE can we get this thing ripping already? @JACK_TRADZ

0 · Reply

TheSniperGuy Jan. 14 at 4:03 PM

$SNSE If you're seriouse about catching small-cap runners or any runners early you learn by yourself!

0 · Reply

Mach777 Jan. 13 at 4:03 PM

$SNSE It’s been a great month. What would this do with some volume…

0 · Reply

Guptasulo Jan. 12 at 1:37 PM

2 · Reply

ChartChartist Jan. 10 at 11:44 PM

$SCNI sitting $MTEX lets go sexy $SNSE climbing channel $ENVB idk okay tho $HWH lets gooo. #1 ticker hwh , get on it

0 · Reply

SuperGreenToday Jan. 9 at 11:02 PM

$SNSE

0 · Reply

Biotechguy21 Jan. 9 at 12:47 PM

$AGEN $IMMX $INKT $SNSE two of these are huge pos stocks. And add $PTIX and you have a trifecta of 💩

0 · Reply

Guptasulo Jan. 9 at 7:00 AM

1 · Reply

Katherine_Clayton_11 Jan. 8 at 3:55 PM

0 · Reply

IAmMsMoneyMaker Jan. 7 at 9:29 PM

$AFJK Is set to RUN! 🚀 🚀 🚀 🚀 So are…$PAVM & $SNSE ALL ABOUT THE TIMING!!! ⏳ ⌛️

0 · Reply

etrade Jan. 7 at 8:14 PM

$SNSE close watch above 11.9 its going wild!

0 · Reply

joe77w Jan. 7 at 3:04 PM

$SNSE 20 USD likely with merger news imo

1 · Reply

skyrockets_Inc Jan. 7 at 2:55 PM

$SNSE Former CEO got a new job. When is our RM/asset sale happening here? Thoughts?

1 · Reply

AnnaLiHard Jan. 7 at 1:09 PM

$SNSE I’m watching and waiting. Holding on to see where this rocket goes! Hopefully up!!!

0 · Reply

Investor1337 Jan. 7 at 5:14 AM

$SNSE starting a pos here

0 · Reply

Stock_Catcher Jan. 7 at 2:55 AM

Wealthy Wednesday Watchlist Pt.5 $MNTS $RGC $ALT $DJT $SNSE Let's Bank Tomorrow 🔥

1 · Reply

LeftyT Jan. 6 at 10:26 PM

$SLS Added another 500 sh at 4.10 today. Dips like this are a solid buying opportunity. When $ARWR dipped yesterday I added more at 62.11 and today it was up 15%. Market manipulation is rampant in low volume small cap bios these days. You need to look at the technology and market cap potential, not the day to day pricing manipulation. This is especially true when weekly options are in play, like with SLS, ALT, and ANVS, as they're used by shorts as cheap hedging on aggressive short plays. Also added some $SNSE this morning and starting to build up my small position there. Do your research folks. Focus on current value and future potential, not on manipulated day trading moves.

0 · Reply

Baseball89 Jan. 6 at 8:40 PM

$SNSE Seems promising. $NCNA --quiet but is gonna wake up soon imo. Solid,no r/s, primed for a breakout.

0 · Reply

ClutchTrader Jan. 6 at 6:27 PM

$SNSE Over $11 incoming! More buying flowing in and large orders too!

0 · Reply

skyrockets_Inc Jan. 6 at 6:06 PM

$SNSE OK I added another 1k shares. I couldn't resist.

0 · Reply

paul29m Jan. 6 at 4:55 PM

$SNSE lol well my timing must suck because once I placed my order it shot up right away. Instead of 20k shares at 10.10, I got a whole 826 shares. :(

0 · Reply

JdNews Jan. 6 at 4:51 PM

$SNSE 👀

0 · Reply

Market Cap	14.83M
Revenue (ttm)	0.00
Net Income (ttm)	-30.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	23,900
Avg Vol	84,032
Day's Range	N/A - N/A
Shares Out	1.26M
Stochastic %K	99%
Beta	0.28
Analysts	Hold
Price Target	$35.00